SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 159 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2014. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $66,000 | -16.5% | 7,316 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $79,000 | -92.0% | 7,316 | -91.5% | 0.00% | -94.9% |
| Q4 2018 | $984,000 | -48.0% | 85,781 | -23.1% | 0.06% | -36.6% |
| Q3 2018 | $1,891,000 | +681.4% | 111,551 | +553.7% | 0.09% | +675.0% |
| Q2 2018 | $242,000 | -96.1% | 17,064 | -96.9% | 0.01% | -90.2% |
| Q2 2015 | $6,175,000 | -35.1% | 556,800 | -8.2% | 0.12% | -36.6% |
| Q1 2015 | $9,514,000 | +3.1% | 606,800 | 0.0% | 0.19% | +1.0% |
| Q4 2014 | $9,230,000 | +41.0% | 606,800 | 0.0% | 0.19% | +28.9% |
| Q3 2014 | $6,546,000 | -29.4% | 606,800 | 0.0% | 0.15% | -28.4% |
| Q2 2014 | $9,268,000 | -15.5% | 606,800 | 0.0% | 0.21% | -12.6% |
| Q1 2014 | $10,971,000 | +30.1% | 606,800 | 0.0% | 0.24% | +28.0% |
| Q4 2013 | $8,430,000 | +32.4% | 606,800 | 0.0% | 0.19% | +20.8% |
| Q3 2013 | $6,367,000 | +34.3% | 606,800 | 0.0% | 0.15% | +25.2% |
| Q2 2013 | $4,742,000 | – | 606,800 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 916,153 | $8,740,000 | 1.27% |
| Casdin Capital, LLC | 1,080,000 | $10,303,000 | 1.13% |
| Rhenman & Partners Asset Management AB | 843,957 | $8,051,000 | 0.94% |
| WASATCH ADVISORS LP | 6,437,908 | $61,418,000 | 0.67% |
| BB BIOTECH AG | 2,650,000 | $25,281,000 | 0.64% |
| Trellus Management Company, LLC | 30,000 | $286,000 | 0.54% |
| Opus Point Partners Management, LLC | 33,529 | $320,000 | 0.43% |
| SECTOR GAMMA AS | 238,857 | $2,279,000 | 0.36% |
| Leisure Capital Management | 37,656 | $359,000 | 0.30% |
| Ceeto Capital Group, LLC | 41,000 | $391,000 | 0.29% |